News

NIH Office of Research on Women’s Health Inviting Comments To Inform the Women’s Health Consensus Conference (WHCC)

The National Institutes of Health (NIH) Office of Research on Women’s Health (ORWH) is planning a Women’s Health Consensus Conference (WHCC) in October 2021, in response to a Congressional request to address NIH research efforts related to women’s health research as well as the following specific conditions, rising maternal morbidity and mortality rates, increasing rates of chronic debilitating conditions in women, and stagnant cervical cancer survival rates. The ORWH is seeking comments and testimonies from the extramural scientific community, professional societies, and the general public regarding the topics mentioned above to assist with identifying research gaps, pitfalls in clinical practices, and obtaining real-life testimonial experiences (direct or indirect) caused by any or all of the listed public health issues.

The Women’s Health Consensus Conference (WHCC) Request for Information is open for public comment through September 15, 2021. Comments must be received by September 15, 2021, to ensure consideration. Comments received after the public comment period has closed may be considered by the Office of Research on Women’s Health.

Submissions must be sent electronically to Elizabeth Barr, Ph.D., WHCC@od.nih.gov.

FOR ADDITIONAL INFORMATION CONTACT:

Questions about this request for information should be directed to Elizabeth Barr, Ph.D., Office of Research on Women’s Health, 6707 Democracy Boulevard, Suite 400, Bethesda, MD 20817, WHCC@od.nih.gov, 301-402-7895.

Further details also available here.

Recent News

11/16/2022

Alliance for Building Better Medicine Names Joy Polefrone as Executive Director

Joy Polefrone, Ph.D. will Lead the Organization in Its Mission to Create a Reliable Supply of Safe, High-Quality, and Affordable Medicines in the U.S. Richmond/Petersburg– Alliance for Building Better Medicine, a coalition of public and private sector stakeholders in the Richmond-Petersburg region, today announced that it has appointed Joy Marie Polefrone, Ph.D., as the organization’s executive director.

11/16/2022

Richmond-area-based pharma company Indivior buys NARCAN developer Opiant, aims to launch new overdose reversal agent

Richmond, VA, (Richmond Times Dispatch) – Chesterfield-based Indivior, already in the business of opioid addiction treatment, is branching into overdose protection. The global pharmaceutical company entered into an agreement to acquire Opiant Pharmaceuticals Inc. for a reported $145 million. Indivior is the company best known for producing Suboxone, a commonly used medication in treating opioid addiction.

11/16/2022

BRAINBox Solutions Enrolls 1000th Patient in Pivotal, HeadSMART II Clinical Study of BRAINBox TBI Concussion Diagnostic and Prognostic Test

RICHMOND, VA. – BRAINBox Solutions today announced that the company  has enrolled the 1,000th patient in the pivotal, HeadSMART II study of its concussion diagnostic  and prognostic test, BRAINBox TBI. The multi-national, multi-site, trial is designed to  support an application for regulatory clearance by the U.S. FDA.   “We are developing the BRAINBox TBI (Traumatic Brain